Effect of Dynamic Arterial Elastance and Assisted Fluid Management Software Guided Adjustment of Vasopressor and Fluid Therapy in Septic Shock Resuscitation; A Pilot Study

What this Trial Is About

Researchers are evaluating the benefit of using dynamic arterial elastance (Eadyn) and Assisted Fluid Management (AFM) software to guide fluid and vasopressor therapy in patients with septic shock who are mechanically ventilated. Septic shock involves systemic inflammation causing low blood pressure and organ dysfunction, and managing fluids and vasopressors precisely is challenging. This pilot study compares the AFM and Eadyn-guided therapy to the standard care approach to see if it can reduce the time it takes for shock to reverse. The study has two groups: one receiving standard care based on septic shock guidelines including vasopressors like norepinephrine and fluid challenges guided by blood pressure and central venous pressure; the other group receives standard care plus AFM and Eadyn-guided treatment. This involves using a monitoring device to measure stroke volume changes and arterial elastance to guide fluid administration and vasopressor dosing every 10 minutes until blood pressure targets are met. Fluid therapy is adjusted based on specific predictions and arterial tone measurements. Participants will be assessed through invasive arterial pressure monitoring, echocardiograms, and clinical measures such as urine output, capillary refill time, and serum lactate levels. Researchers will track outcomes including time to shock reversal within 28 days, vasopressor dose and duration, fluid volume given, hospital length of stay, mortality, and kidney function measures. Safety and effectiveness data will be collected throughout the trial, which runs until April 2028.

Effect of Dynamic Arterial Elastance and Assisted Fluid Management Software Guided Resuscitation in Septic Shock: Pilot Study